{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:16:04Z","timestamp":1792106164229,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["metabolismjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.metabol.2024.156111","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T22:43:59Z","timestamp":1734734639000},"page":"156111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["NORAD exacerbates metabolic dysfunction-associated steatotic liver disease development via the miR-511-3p\/Rock2 axis and inhibits ubiquitin-mediated degradation of ROCK2"],"prefix":"10.1016","volume":"164","author":[{"given":"Xu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfeng","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2024.156111_bb0005","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2024.156111_bb0010","doi-asserted-by":"crossref","DOI":"10.59717\/j.xinn-med.2024.100064","article-title":"New-onset age of metabolic-associated fatty liver disease and incident cardiovascular diseases: findings from prospective cohort","volume":"2","author":"Zheng","year":"2024","journal-title":"Innov Med"},{"key":"10.1016\/j.metabol.2024.156111_bb0015","article-title":"Complications, morbidity and mortality of nonalcoholic fatty liver disease","volume":"111S","author":"Mantovani","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156111_bb0020","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41575-020-0316-6","article-title":"From NAFLD to MAFLD: when pathophysiology succeeds","volume":"17","author":"Tilg","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.156111_bb0025","doi-asserted-by":"crossref","DOI":"10.1177\/20420188221145549","article-title":"MAFLD: a multisystem disease","volume":"14","author":"Pipitone","year":"2023","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.metabol.2024.156111_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155609","article-title":"LncRNA Nron deficiency protects mice from diet-induced adiposity and hepatic steatosis","volume":"148","author":"Liu","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156111_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.metabol.2019.01.018","article-title":"LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6","volume":"94","author":"Huang","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156111_bb0040","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1038\/s41418-023-01183-4","article-title":"GAS5 protects against nonalcoholic fatty liver disease via miR-28a-5p\/MARCH7\/NLRP3 axis-mediated pyroptosis","volume":"30","author":"Chen","year":"2023","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.metabol.2024.156111_bb0045","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2015.12.017","article-title":"Noncoding RNA NORAD regulates genomic stability by sequestering PUMILIO proteins","volume":"164","author":"Lee","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.metabol.2024.156111_bb0050","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41586-018-0453-z","article-title":"The NORAD lncRNA assembles a topoisomerase complex critical for genome stability","volume":"561","author":"Munschauer","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2024.156111_bb0055","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41586-021-03633-w","article-title":"NORAD-induced Pumilio phase separation is required for genome stability","volume":"595","author":"Elguindy","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2024.156111_bb0060","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01215-18","article-title":"Association between MicroRNA-373 and long noncoding RNA NORAD in hepatitis C virus-infected hepatocytes impairs Wee1 expression for growth promotion","volume":"92","author":"Sur","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.metabol.2024.156111_bb0065","doi-asserted-by":"crossref","first-page":"12051","DOI":"10.1002\/jcp.27869","article-title":"The long noncoding RNA NORAD enhances the TGF-beta pathway to promote hepatocellular carcinoma progression by targeting miR-202-5p","volume":"234","author":"Yang","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.metabol.2024.156111_bb0070","first-page":"2257","article-title":"lncRNA NORAD promotes hepatocellular carcinoma progression via regulating miR-144-3p\/SEPT2","volume":"12","author":"Tian","year":"2020","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.metabol.2024.156111_bb0075","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.arcmed.2020.02.009","article-title":"Transthyretin regulated by linc00657\/miR-205-5p promoted cholesterol metabolism by inducing SREBP2-HMGCR and inhibiting LXR\u03b1-CYP7A1","volume":"51","author":"Zuo","year":"2020","journal-title":"Arch Med Res"},{"key":"10.1016\/j.metabol.2024.156111_bb0080","article-title":"miR-511-3p promotes hepatic sinusoidal obstruction syndrome by activating hedgehog pathway via targeting Ptch1","volume":"321","author":"Yang","year":"2021","journal-title":"Am J Physiol-Gastr L"},{"key":"10.1016\/j.metabol.2024.156111_bb0085","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ajpath.2017.12.007","article-title":"miRNA in rat liver sinusoidal endothelial cells and hepatocytes and application to circulating biomarkers that discern pathogenesis of liver injuries","volume":"188","author":"Oda","year":"2018","journal-title":"Am J Pathol"},{"key":"10.1016\/j.metabol.2024.156111_bb0090","doi-asserted-by":"crossref","DOI":"10.1080\/15592294.2023.2239592","article-title":"ZNF143 inhibits hepatocyte mitophagy and promotes non-alcoholic fatty liver disease by targeting increased lncRNA NEAT1 expression to activate ROCK2 pathway","volume":"18","author":"Dong","year":"2023","journal-title":"Epigenetics"},{"key":"10.1016\/j.metabol.2024.156111_bb0095","first-page":"26","article-title":"The effects of RKI-1447 in a mouse model of nonalcoholic fatty liver disease induced by a high-fat diet and in HepG2 human hepatocellular carcinoma cells treated with oleic acid","author":"Wang","year":"2020","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.metabol.2024.156111_bb0100","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2024.156111_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.100918","article-title":"Protocol for the assessment of mTOR activity in mouse primary hepatocytes","volume":"2","author":"Plata-Gomez","year":"2021","journal-title":"STAR Protoc"},{"key":"10.1016\/j.metabol.2024.156111_bb0110","first-page":"1293","article-title":"Detection of protein ubiquitination","volume":"30","author":"Choo","year":"2009","journal-title":"J Vis Exp"},{"key":"10.1016\/j.metabol.2024.156111_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155516","article-title":"Metformin-induced TTP mediates communication between Kupffer cells and hepatocytes to alleviate hepatic steatosis by regulating lipophagy and necroptosis","volume":"141","author":"Park","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156111_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155835","article-title":"Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges","volume":"154","author":"Kokkorakis","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156111_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155935","article-title":"Resmetirom for MASH patients with diabetes: challenges and opportunities in the real world","volume":"156","author":"Lian","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156111_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155661","article-title":"Hepatocyte-secreted FAM3D ameliorates hepatic steatosis by activating FPR1-hnRNP U-GR-SCAD pathway to enhance lipid oxidation","volume":"146","author":"Hu","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.156111_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.714787","article-title":"Non-coding RNA activated by DNA damage: review of its roles in the carcinogenesis","volume":"9","author":"Ghafouri-Fard","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.metabol.2024.156111_bb0140","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4093\/dmj.2021.0197","article-title":"Rho-kinase as a therapeutic target for nonalcoholic fatty liver diseases","volume":"45","author":"Sousa-Lima","year":"2021","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.metabol.2024.156111_bb0145","article-title":"ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis","volume":"4","author":"Nalkurthi","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.metabol.2024.156111_bb0150","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1096\/fj.201901174RR","article-title":"ROCK2 inhibition enhances the thermogenic program in white and brown fat tissue in mice","volume":"34","author":"Wei","year":"2020","journal-title":"FASEB J"},{"key":"10.1016\/j.metabol.2024.156111_bb0155","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41467-017-00129-y","article-title":"ROCKII inhibition promotes the maturation of human pancreatic beta-like cells","volume":"8","author":"Ghazizadeh","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2024.156111_bb0160","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1182\/blood.2021014448","article-title":"Three US Food and Drug Administration-approved therapies for chronic GVHD","volume":"139","author":"Zeiser","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.metabol.2024.156111_bb0165","first-page":"34","article-title":"Novel Rho associated coiled kinase 2 (ROCK2) inhibitor reduces steatosis and fibrosis in mice model of liver disease","author":"Ali","year":"2020","journal-title":"FASEB J"},{"key":"10.1016\/j.metabol.2024.156111_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26164747","article-title":"ROCK2-specific inhibitor KD025 suppresses adipocyte differentiation by inhibiting casein kinase 2","volume":"26","author":"Tran","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.metabol.2024.156111_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.702025","article-title":"Exercise counterbalances rho\/ROCK2 signaling impairment in the skeletal muscle and ameliorates insulin sensitivity in obese mice","volume":"12","author":"Munoz","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.metabol.2024.156111_bb0180","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1210\/en.2011-1036","article-title":"Regulation of glucose transport by ROCK1 differs from that of ROCK2 and is controlled by actin polymerization","volume":"153","author":"Chun","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2024.156111_bb0185","article-title":"Complex regulation of PKCbeta2 and PDK-1\/AKT by ROCK2 in diabetic heart","volume":"9","author":"Lin","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.metabol.2024.156111_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140255","article-title":"Novel endogenous, insulin-stimulated Akt2 protein interaction partners in L6 myoblasts","volume":"10","author":"Caruso","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.metabol.2024.156111_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314788","article-title":"Novel dual AChE and ROCK2 inhibitor induces neurogenesis via PTEN\/AKT pathway in Alzheimer\u2019s disease model","volume":"23","author":"Moreira","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2024.156111_bb0200","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.191","article-title":"ROCK2 is a major regulator of axonal degeneration, neuronal death and axonal regeneration in the CNS","volume":"5","author":"Koch","year":"2014","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.metabol.2024.156111_bb0205","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.febslet.2015.03.004","article-title":"ROCK2 promotes HCC proliferation by CEBPD inhibition through phospho-GSK3beta\/beta-catenin signaling","volume":"589","author":"Li","year":"2015","journal-title":"FEBS Lett"},{"key":"10.1016\/j.metabol.2024.156111_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115816","article-title":"TIPE2 ameliorates neuroinflammation and cognitive impairment in sepsis-associated encephalopathy through regulating RhoA\/ROCK2-NF-kappaB signaling pathway","volume":"217","author":"Yuan","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.metabol.2024.156111_bb0215","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/hep.30062","article-title":"Ubiquitin-specific peptidase 10 (USP10) inhibits hepatic steatosis, insulin resistance, and inflammation through Sirt6","volume":"68","author":"Luo","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2024.156111_bb0220","first-page":"14","article-title":"Lysosomal-associated protein transmembrane 5 ameliorates non-alcoholic steatohepatitis by promoting the degradation of CDC42 in mice","author":"Jiang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2024.156111_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2021.05.019","article-title":"Tripartite motif 16 ameliorates nonalcoholic steatohepatitis by promoting the degradation of phospho-TAK1","volume":"33","author":"Wang","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2024.156111_bb0230","article-title":"SNRK modulates mTOR-autophagy pathway for liver lipid homeostasis in MAFLD","volume":"24","author":"Lin","year":"2024","journal-title":"Mol Ther"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524003391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524003391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T23:29:36Z","timestamp":1740353376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049524003391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":46,"alternative-id":["S0026049524003391"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156111","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NORAD exacerbates metabolic dysfunction-associated steatotic liver disease development via the miR-511-3p\/Rock2 axis and inhibits ubiquitin-mediated degradation of ROCK2","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2024.156111","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156111"}}